The Glp-1 Analog Liraglutide Protects Against Angiotensin II and Pressure Overload-Induced Cardiac Hypertrophy via PI3K/Akt1 and AMPKa Signaling
The Glp-1 analog, liraglutide (Lir), has been shown to reduce infarct size and improve cardiac function after myocardial ischemia in rodents with or without diabetes. However, the effect of Lir on angiotensin II (AngII) and pressure overload induced cardiac hypertrophy in nondiabetic mice and the un...
Main Authors: | Ran Li, Yingguang Shan, Lu Gao, Xi Wang, Xule Wang, Fang Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-06-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.00537/full |
Similar Items
-
First GLP-1 analog liraglutide: the result of clinical trails on efficacy
by: Alexander Sergeevich Ametov, et al.
Published: (2011-12-01) -
Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update
by: Collin Vandemark, et al.
Published: (2023-02-01) -
Protective effect of GLP-1 analog liraglutide on podocytes in mice with diabetic nephropathy
by: Shaomin Shi, et al.
Published: (2023-09-01) -
The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function
by: Małgorzata Wajdlich, et al.
Published: (2024-02-01) -
Liraglutide attenuates cardiac remodeling and improves heart function after abdominal aortic constriction through blocking angiotensin II type 1 receptor in rats
by: Zheng RH, et al.
Published: (2019-08-01)